New Issue of the Consortium PSYCHIATRICUM is available - Vol 6, No 2

The issue opens with an investigation into osteoporosis risks associated with anticonvulsant therapy, proposing revised treatment protocols for epilepsy that account for pharmacological generation differences.

A subsequent original research article examines anticipatory dysfunction mechanisms in schizophrenia patients, addressing the critical question: Does the schizophrenic brain lose its capacity to process probabilistic future events?

Further contributing to this issue is a pivotal study validating the Russian adaptation of the Inventory of Motivations for Suicide Attempts (IMSA) in adolescent populations. The authors provide nuanced analysis of gender-specific factors underlying suicidal behavior in youths.

The issue also includes a comprehensive review analyzing schizophrenia risk in individuals with schizotypal traits, synthesizing data from 45 studies. This work identifies symptom clusters reflecting genetic predisposition to schizophrenia and evaluates the feasibility of preclinical psychosis risk assessment.

Another review focuses on SLC6A4 gene polymorphisms and their contribution to addictive disorder susceptibility, with particular attention to allelic distribution patterns across ethnic groups and antidepressant treatment response variability.

Concluding this edition is a historical retrospective examining Professor I.P. Lapin's seminal contributions to psychopharmacology. The authors meticulously analyze his depression pathogenesis hypotheses, his transformative insights into serotonin's role, and their implications for developing selective serotonin reuptake inhibitors (SSRIs).

Read the full issue: Consortium Psychiatricum, 2025, Volume 2